Based on the positive data presented at ESMO, we
Post# of 157598
(Total Views: 396)
Posted On: 09/30/2025 9:41:54 AM
Based on the positive data presented at ESMO, we will shortly submit a follow-up Phase II proof of concept (POC) protocol for PD-L1-negative patients with mTNBC. These patients, currently ineligible for ICI therapy, will receive leronlimab plus standard chemotherapy, followed by a regimen of leronlimab with an ICI.
https://www.cytodyn.com/newsroom/press-releas...areholders
https://www.cytodyn.com/newsroom/press-releas...areholders
(7)
(0)